Immunic (IMUX) Earnings Date & Reports

Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis... Show more

Industry: #Pharmaceuticals Major

Get AI intraday signals

A.I. Advisor

published Earnings

IMUX is expected to report earnings to fall 91.97% to -8 cents per share on August 06

Q2'26

Est.

$-0.09

Q1'26

Missed

by $1.00

Q4'25

Missed

by $0.53

Q3'25

Beat

by $0.02

Q2'25

Missed

by $0.03

The last earnings report on May 13 showed earnings per share of -108 cents, missing the estimate of -7 cents. With 261.36K shares outstanding, the current market capitalization sits at 173.95M.

View a ticker or compare two or three

Compare

IMUX

Setup

Daily Signal:

Description

Gain/Loss:

Interact to see
Advertisement

A.I.Advisor

published price charts

Last 5 trading days

View AI-Driven Trading for IMUX